Literature DB >> 6120710

Clobazam kinetics in the elderly.

D J Greenblatt, M Divoll, S K Puri, I Ho, M A Zinny, R I Shader.   

Abstract

1 The effects of age and sex on the disposition of clobazam (CBZ), a 1.5-benzodiazepine derivative, were evaluated in a series of 29 healthy volunteers aged 18 to 72 years, who ingested single 20 mg oral doses. CBZ kinetics were determined from multiple plasma concentrations measured during 7 days after the dose. 2 CBZ was rapidly absorbed, with peak levels reached an average of 1.5 h after dosing (range 0.5--2.5 h). Mean absorption half-life was 19.7 min. Absorption kinetics were not influenced by age of sex. 3 Elimination half-life ranged from 11 to 77 h, and was significantly longer in elderly v young males (48 v 17 h, P less than 0.01). In women, half-life also increased with age, but differences between young and elderly women were less striking (31 v 49 h, P less than 0.05). 4 Volume of distribution (Vd) was influenced by age and sex. Vd became larger with age regardless of sex, and within each age group was larger in women than in men. Total clearance was unrelated to age in women, but declined significantly with age in men (P less than 0.01). 5 The mean free fraction for CBZ in plasma was 11.5% (range 8.6--15.0%), and tended to increase with age, partly due to a significant age-related decline in plasma albumin concentration (r = -0.68, P less than 0.001). Correction of Vd and clearance for individual differences in binding did not alter their relation to age and sex. 6 As in the case of other benzodiazepines biotransformed by oxidative pathways, the capacity for N-demethylation of CBZ declines with age in men, but age has a minimal effect on CBZ clearance in women.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6120710      PMCID: PMC1401958          DOI: 10.1111/j.1365-2125.1981.tb01281.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

Review 1.  Clobazam: pharmacological and therapeutic profile.

Authors:  G W Hanks
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

2.  Altered elimination of desmethyldiazepam in the elderly.

Authors:  U Klotz; P Müller-Seydlitz
Journal:  Br J Clin Pharmacol       Date:  1979-01       Impact factor: 4.335

3.  Effect of age on the pharmacokinetics of diazepam given in conjunction with spinal anesthesia.

Authors:  J Kanto; M Mäenpää; R Mäntylä; R Sellman; E Valovirta
Journal:  Anesthesiology       Date:  1979-08       Impact factor: 7.892

4.  Pharmacokinetic and clinical implications of quinidine protein binding.

Authors:  E Woo; D J Greenblatt
Journal:  J Pharm Sci       Date:  1979-04       Impact factor: 3.534

5.  Electron-capture GLC determination of clobazam and desmethylclobazam in plasma.

Authors:  D J Greenblatt
Journal:  J Pharm Sci       Date:  1980-11       Impact factor: 3.534

6.  Diazepam disposition determinants.

Authors:  D J Greenblatt; M D Allen; J S Harmatz; R I Shader
Journal:  Clin Pharmacol Ther       Date:  1980-03       Impact factor: 6.875

7.  Effects of age and other drugs on benzodiazepine kinetics.

Authors:  D J Greenblatt; R I Shader
Journal:  Arzneimittelforschung       Date:  1980

Review 8.  Clobazam: a review of its pharmacological properties and therapeutic use in anxiety.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1980-09       Impact factor: 9.546

9.  Desmethyldiazepam kinetics in the elderly after oral prazepam.

Authors:  M D Allen; D J Greenblatt; J S Harmatz; R I Shader
Journal:  Clin Pharmacol Ther       Date:  1980-08       Impact factor: 6.875

  9 in total
  27 in total

Review 1.  Hepatic drug metabolism and aging.

Authors:  C Durnas; C M Loi; B J Cusack
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly. Therapeutic considerations (Part II).

Authors:  D J Greenblatt; J S Harmatz; R I Shader
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

3.  Age-dependence and free fatty acid modulation of binding kinetics at the benzodiazepine binding site of serum albumin in neonates and adults determined using fast reaction methods.

Authors:  G Menke; P Pfister; S Sauerwein; I Rietbrock; B G Woodcock; N Rietbrock
Journal:  Br J Clin Pharmacol       Date:  1987-04       Impact factor: 4.335

Review 4.  Clobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studies.

Authors:  Jose de Leon; Edoardo Spina; Francisco J Diaz
Journal:  Ther Drug Monit       Date:  2013-02       Impact factor: 3.681

Review 5.  Anticonvulsant therapy in aged patients. Clinical pharmacokinetic considerations.

Authors:  I Bernus; R G Dickinson; W D Hooper; M J Eadie
Journal:  Drugs Aging       Date:  1997-04       Impact factor: 3.923

6.  Single dose pharmacokinetics and pharmacodynamics of oral loprazolam in the elderly.

Authors:  C G Swift; M R Swift; S I Ankier; A Pidgen; J Robinson
Journal:  Br J Clin Pharmacol       Date:  1985-08       Impact factor: 4.335

7.  The disposition of antipyrine and its metabolites in young and elderly healthy volunteers.

Authors:  J Posner; M Danhof; M W Teunissen; D D Breimer; P D Whiteman
Journal:  Br J Clin Pharmacol       Date:  1987-07       Impact factor: 4.335

8.  The relationship between phenazone (antipyrine) metabolite formation and theophylline metabolism in healthy and frail elderly women.

Authors:  K Groen; M A Horan; N A Roberts; R S Gulati; B Miljkovic; E J Jansen; V Paramsothy; D D Breimer; C F van Bezooijen
Journal:  Clin Pharmacokinet       Date:  1993-08       Impact factor: 6.447

Review 9.  Benzodiazepine poisoning. Clinical and pharmacological considerations and treatment.

Authors:  P Gaudreault; J Guay; R L Thivierge; I Verdy
Journal:  Drug Saf       Date:  1991 Jul-Aug       Impact factor: 5.606

Review 10.  The problems and pitfalls of NSAID therapy in the elderly (Part II).

Authors:  A G Johnson; R O Day
Journal:  Drugs Aging       Date:  1991-05       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.